Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 2Dermatologic 1CNS 1

Conditions

Melanoma 109Lymphoma, T-Cell, Cutaneous 27Mycosis Fungoides 22Skin Neoplasms 20Sezary Syndrome 19Lymphoma, Non-Hodgkin 16Lymphoma, Follicular 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Neoplasm Metastasis 13Lymphoma, Mantle-Cell 13Lymphoma, Large-Cell, Immunoblastic 13Lymphoma, Large-Cell, Anaplastic 13Lymphoma, Large B-Cell, Diffuse 13Lymphoma, B-Cell, Marginal Zone 13Lymphoma 13Leukemia, Lymphocytic, Chronic, B-Cell 13Burkitt Lymphoma 13Hodgkin Disease 12Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 11Immunoblastic Lymphadenopathy 11Waldenstrom Macroglobulinemia 10Keratosis, Actinic 10Breast Neoplasms 10Uveal Melanoma 9Lymphoma, Extranodal NK-T-Cell 9Leukemia, Myeloid, Acute 9Leukemia, Hairy Cell 9Intraocular Lymphoma 9Carcinoma, Basal Cell 9Neoplasms 8

Interventions

antineoplaston AS 2-1 1antineoplaston A10 1Complementary Therapies 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Growth Hormone-Secreting Pituitary Adenoma × Dermatologic × Clear all
NCT00003514 2013-07-10

Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy

National Cancer Institute (NCI)

Phase 2 Withdrawn
DermatologicEndocrine

Pituitary Neoplasms, Somatostatinoma, Carcinoma, Merkel Cell, Carcinoma, Islet Cell, Carcinoma, Neuroendocrine, Growth Hormone-Secreting Pituitary Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡